Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma

• XueYin Xu ,

  Contributed equally to this work with: XueYin Xu, Lian Tang, XiangHua Piao

  Roles Data curation

  Affiliation Department of Pharmacy, Nantong First People’s Hospital, Southeast University, Nantong, Jiangsu, China

  ⨯
• Lian Tang ,

  Contributed equally to this work with: XueYin Xu, Lian Tang, XiangHua Piao

  Roles Data curation

  Affiliation Department of Pharmacy, Nantong First People’s Hospital, Southeast University, Nantong, Jiangsu, China

  ⨯
• XiangHua Piao ,

  Contributed equally to this work with: XueYin Xu, Lian Tang, XiangHua Piao

  Roles Data curation

  Affiliation Department of Pharmacy, Jiangwan Hospital of Shanghai Hongkou District, Shanghai, China

  ⨯
• ShaoQing Zhan,

  Roles Data curation

  Affiliation Department of Pharmacy, Nantong First People’s Hospital, Southeast University, Nantong, Jiangsu, China

  ⨯
• Yong Chen ,

  Roles Data curation

  * E-mail: 929083891@qq.com (PF); chenyong20242024@126.com (YC)

  Affiliation Department of Pharmacy, Nantong First People’s Hospital, Southeast University, Nantong, Jiangsu, China

  ⨯
• PanFeng Feng

  Roles Conceptualization

  * E-mail: 929083891@qq.com (PF); chenyong20242024@126.com (YC)

  Affiliations Department of Pharmacy, Nantong First People’s Hospital, Southeast University, Nantong, Jiangsu, China, Nantong Key Laboratory of Innovative Research on Rheumatology and Immunology‌‌, Nantong, Jiangsu, China, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China

  https://orcid.org/0000-0001-7817-7971

  ⨯